Table 2.
Cytokine–receptor axes identified in this study.
| Axis | Cytokine/receptor | Description | Correlation among LUSC cohort | Drug |
|---|---|---|---|---|
| CCL3L1_CCR1 | CCL3L1 | C-C motif chemokine ligand 3 like 1 | R = 0.43, P = 1.1e−12 | No record |
| CCR1 | C-C motif chemokine receptor 1 | DAPTA, BX 471, CCL3 ,CCL4, J 113863 | ||
| CCL3_CCR1 | CCL3 | C-C motif chemokine ligand 3 | R = 0.82, P < 2.2e−16 | ROX-888 |
| CCR1 | C-C motif chemokine receptor 1 | DAPTA, BX 471, CCL3, CCL4, J 113863 | ||
| CCL2_CCR2 | CCL2 | C-C motif chemokine ligand 2 | R = 0.66, P < 2.2e−16 | Danazol, Atorvastatin, Simvastatin, Chondroitin sulfate, Risperidone |
| CCR2 | C-C motif chemokine receptor 2 | INCB3284, CCX915, Plozalizumab, MK-0812, DAPTA | ||
| CCL3_CCR5 | CCL3 | C-C motif chemokine ligand 3 | R = 0.73, P < 2.2e−16 | ROX-888 |
| CCR5 | C-C motif chemokine receptor 5 | Maraviroc, Dexamethasone, Efavirenz, Etravirine, Ritonavir | ||
| CCL4_CCR5 | CCL4 | C-C motif chemokine ligand 4 | R = 0.87, P < 2.2e−16 | No record |
| CCR5 | C-C motif chemokine receptor 5 | Maraviroc, Dexamethasone, Efavirenz, Etravirine, Ritonavir | ||
| CCL4L2_VSIR | CCL4L2 | C-C motif chemokine ligand 4 like 2 | R = 0.43, P = 2.1e−12 | No record |
| VSIR | V-set immunoregulatory receptor | No record |